Carlette Graham, MD
Pulmonary Disease · Riverdale, GANPI 1417921552
Payments from drug & device makers
Across 694 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Boehringer Ingelheim$1K
- Sanofi$720
- Grifols USA, LLC$671
- Regeneron Healthcare Solutions, Inc.$544
- plus $4K from 33 others
What the payments were for
- Food & beverage$13,77498%
- Education$2922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 210 | $3,946 |
| AstraZeneca | 129 | $2,703 |
| Boehringer Ingelheim | 65 | $1,153 |
| Sanofi | 29 | $720 |
| Grifols USA, LLC | 37 | $671 |
| Regeneron Healthcare Solutions, Inc. | 23 | $544 |
| Actelion Pharmaceuticals US, Inc. | 22 | $531 |
| Mylan Specialty L.p. | 23 | $528 |
| Baxter Healthcare | 22 | $474 |
| Amgen | 24 | $470 |
| United Therapeutics Corporation | 14 | $279 |
| Insmed, Inc. | 11 | $214 |
| Mallinckrodt Enterprises LLC | 9 | $180 |
| Sanofi-aventis U.S. LLC | 2 | $178 |
| Mallinckrodt Hospital Products Inc. | 3 | $131 |
| Advanced Respiratory, Inc | 6 | $112 |
| Paratek Pharmaceuticals, Inc. | 6 | $111 |
| Novartis | 7 | $106 |
| Philips North America LLC | 5 | $90 |
| Verona Pharma, Inc. | 3 | $82 |
| Merck | 4 | $82 |
| Pulmonx Corporation | 4 | $81 |
| Pfizer | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 5 | $72 |
| Jazz Pharmaceuticals Inc. | 3 | $68 |
| Viatris Specialty LLC | 3 | $62 |
| Shire North American Group Inc | 3 | $57 |
| Genentech USA, Inc. | 3 | $53 |
| Inari Medical, Inc. | 2 | $53 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Circassia Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Viiv Healthcare Company | 1 | $20 |
| Gilead | 1 | $19 |
| Optinose US, Inc. | 1 | $15 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,066 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,024 | $853,150 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 206 | $159,139 |
| Breo ElliptaFluticasone/Vilanterol | 181 | $95,048 |
| Spiriva RespimatTiotropium Bromide | 86 | $69,240 |
| SymbicortBudesonide/Formoterol Fumarate | 197 | $65,983 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,396 | $41,948 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $28,337 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $27,655 |
| Spiriva HandihalerTiotropium Bromide | 27 | $21,925 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 94 | $21,266 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $20,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $20,520 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $18,428 |
| DuleraMometasone/Formoterol | 27 | $13,852 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 54 | $11,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,946 | $995,7961,291 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,703 | $225,122403 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,153 | $116,005142 claims |
| MerckDulera | $82 | $13,85227 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $72 | $10,70730 claims |
| Hikma Pharmaceuticals USAEpinephrine | $38 | $3,28317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Riverdale
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.